Your browser doesn't support javascript.
loading
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Roussel, Murielle; Moreau, Philippe; Hebraud, Benjamin; Laribi, Kamel; Jaccard, Arnaud; Dib, Mamoun; Slama, Borhane; Dorvaux, Véronique; Royer, Bruno; Frenzel, Laurent; Zweegman, Sonja; Klein, Saskia K; Broijl, Annemiek; Jie, Kon-Siong; Wang, Jianping; Vanquickelberghe, Veronique; de Boer, Carla; Kampfenkel, Tobias; Gries, Katharine S; Fastenau, John; Sonneveld, Pieter.
Afiliación
  • Roussel M; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
  • Moreau P; Hematology, University Hospital Hôtel-Dieu, Nantes, France.
  • Hebraud B; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
  • Laribi K; Centre Hospitalier, Le Mans, France.
  • Jaccard A; Centre Hospitalier Universitaire de Limoges, Limoges, France.
  • Dib M; Centre Hospitalier Régional Universitaire-Hôpital du Bocage, Angers, France.
  • Slama B; Centre Hospitalier H Duffaut, Avignon, France.
  • Dorvaux V; Hôpital de Mercy (Centre Hospitalier Régional Metz-Thionville), Metz, France.
  • Royer B; Hôpital St-Louis, Paris, France.
  • Frenzel L; Hôpital Necker, Paris, France.
  • Zweegman S; Amsterdam Universitair Medische Centra, Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, Netherlands.
  • Klein SK; Meander Medical Centre, Amersfoort, Netherlands.
  • Broijl A; Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Jie KS; Zuyderland MC, Sittard, Netherlands.
  • Wang J; Janssen Global Services, Raritan, NJ, USA.
  • Vanquickelberghe V; Janssen Research and Development, Beerse, Belgium.
  • de Boer C; Janssen Research and Development, Leiden, Netherlands.
  • Kampfenkel T; Janssen Research and Development, Leiden, Netherlands.
  • Gries KS; Janssen Global Services, Raritan, NJ, USA.
  • Fastenau J; Janssen Global Services, Raritan, NJ, USA.
  • Sonneveld P; Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: p.sonneveld@erasmusmc.nl.
Lancet Haematol ; 7(12): e874-e883, 2020 Dec.
Article en En | MEDLINE | ID: mdl-33242444
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Calidad de Vida / Talidomida / Dexametasona / Bortezomib / Anticuerpos Monoclonales / Mieloma Múltiple Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies / Qualitative_research Límite: Female / Humans / Male Idioma: En Revista: Lancet Haematol Año: 2020 Tipo del documento: Article País de afiliación: Francia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Calidad de Vida / Talidomida / Dexametasona / Bortezomib / Anticuerpos Monoclonales / Mieloma Múltiple Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies / Qualitative_research Límite: Female / Humans / Male Idioma: En Revista: Lancet Haematol Año: 2020 Tipo del documento: Article País de afiliación: Francia